Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

Jane Scott, Kathleen Rosa, Min Fu, Karin Cerri, Monika Peeters, Maria Beumont, Stefan Zeuzem, Donna M Evon, Leen Gilles, Jane Scott, Kathleen Rosa, Min Fu, Karin Cerri, Monika Peeters, Maria Beumont, Stefan Zeuzem, Donna M Evon, Leen Gilles

Abstract

Background: Fatigue is a common symptom of chronic hepatitis C virus (HCV) infection and a frequent side-effect of peginterferon/ribavirin (PR) therapy for HCV. This study evaluated the impact of adding the oral HCV NS3/4A protease inhibitor simeprevir to PR on patient-reported fatigue and health status among patients with chronic HCV genotype 1 infection enrolled in the Phase IIb PILLAR and ASPIRE trials [NCT00882908; NCT00980330].

Methods: Treatment-naïve patients (PILLAR, n = 386) and treatment-experienced patients (ASPIRE, n = 462) were randomized to simeprevir plus PR (simeprevir/PR) or placebo plus PR (placebo/PR). In PILLAR, duration of PR treatment in the simeprevir/PR groups was determined using response-guided therapy (RGT) criteria. PR could be terminated at Week 24, instead of Week 48, if HCV RNA was <25 IU/mL by Week 4 and then undetectable at Weeks 12, 16, and 20. In both studies, patients completed the Fatigue Severity Scale (FSS) and EQ-5D quality-of-life questionnaire in their native language at baseline and throughout the studies up until Week 72.

Results: During the first 24 weeks of treatment, mean FSS total score was increased to a similar degree compared with baseline among patients receiving simeprevir/PR or placebo/PR in both studies indicating increased fatigue severity. Mean FSS scores returned to values comparable with baseline among patients receiving simeprevir/PR after Week 24 in PILLAR (after treatment completion for the majority of patients) and in ASPIRE (after Week 48), consistent with RGT enabling early termination of all treatment at Week 24 in 82.2% of simeprevir/PR-treated patients in the PILLAR study. Similar results were observed for EQ-5D, with simeprevir/PR-treated patients experiencing less time with worse health problems according to EQ-5D scores compared with placebo/PR groups in both studies, and more rapid improvement in health status associated with shorter treatment duration in the PILLAR study.

Conclusions: Combination of simeprevir with PR did not increase patient-reported fatigue severity or health status impairments beyond that reported by patients treated with PR alone. Many patients treated with simeprevir/PR returned to pretreatment fatigue and health status levels sooner due to increased treatment efficacy that enabled shorter duration of all therapy, compared with PR alone.

Figures

Figure 1
Figure 1
PILLAR and ASPIRE trial designs.
Figure 2
Figure 2
Proportion of simeprevir/PR-treated patients achieving SVR24 in the PILLAR and ASPIRE studies.
Figure 3
Figure 3
Change from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR in a) the PILLAR study and b) the ASPIRE study.
Figure 4
Figure 4
Mean change (±SE) from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR according to treatment duration in the PILLAR study.
Figure 5
Figure 5
Mean change from baseline in a) EQ-5D valuation index values and b) EQ-5D VAS for all simeprevir/PR treatment groups combined vs placebo/PR in the PILLAR and ASPIRE studies.
Figure 6
Figure 6
Mean EQ-5D (±SE) changes over time in the Visual Analogue Scale (VAS) by treatment group for patients with and without FSS scores at baseline.

References

    1. World Health Organization: 63rd World Health Assembly. Provisional agenda item 11_12; 25 March 2010. ,
    1. Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means ‘you just haven’t got a normal life any more’. Chronic Illn. 2006;2:121–131.
    1. Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med. 2008;23:1959–1965. doi: 10.1007/s11606-008-0790-y.
    1. Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci. 2002;47:2674–2681. doi: 10.1023/A:1021040702370.
    1. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P, Charlotte F, Piette JC, Moussalli J. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002;9:295–303. doi: 10.1046/j.1365-2893.2002.00364.x.
    1. Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007;52:2531–2539. doi: 10.1007/s10620-006-9708-x.
    1. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012;57:946–952. doi: 10.1016/j.jhep.2012.06.030.
    1. McDonald J, Jayasuriya J, Bindley P, Gonsalvez C, Gluseska S. Fatigue and psychological disorders in chronic hepatitis C. J Gastroenterol Hepatol. 2002;17:171–176. doi: 10.1046/j.1440-1746.2002.02669.x.
    1. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, Ahl B, Manns MP, Boker KW. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41:845–851. doi: 10.1016/j.jhep.2004.07.022.
    1. Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, Rakela J. Emerging evidence of hepatitis C virus neuroinvasion. AIDS. 2005;19(Suppl 3):S140–S144. doi: 10.1097/01.aids.0000192083.41561.00.
    1. Seaman K, Paterson BL, Vallis M, Hirsch G, Peltekian KM. Future directions for investigation of fatigue in chronic hepatitis C viral infection. Chronic Illn. 2009;5:115–128. doi: 10.1177/1742395309104476.
    1. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593. doi: 10.1056/NEJMoa0808010.
    1. Casey LC, Lee WM. Hepatitis C therapy update. Curr Opin Gastroenterol. 2012;28:188–192. doi: 10.1097/MOG.0b013e3283528e1e.
    1. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850. doi: 10.1056/NEJMoa0807650.
    1. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012;19(Suppl 2):1–26. doi: 10.1111/j.1365-2893.2012.01590.x.
    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. doi: 10.1016/S0140-6736(01)06102-5.
    1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi: 10.1056/NEJMoa020047.
    1. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta E Vale A, Wintfeld N, Green J. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40:675–681. doi: 10.1016/j.jhep.2003.12.014.
    1. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012;32(Suppl 1):88–102. doi: 10.1111/j.1478-3231.2011.02699.x.
    1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217. doi: 10.1056/NEJMoa1009482.
    1. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206. doi: 10.1056/NEJMoa1010494.
    1. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918–1929. doi: 10.1002/hep.26641.
    1. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hézode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros P, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M. Simeprevir (TMC435) in treatment-experienced HCV genotype 1 patients; the phase IIb, randomized. Controlled ASPIRE trial. Gastroenterology. 2014;146:430–441. doi: 10.1053/j.gastro.2013.10.058.
    1. Kleinman L, Mannix S, Yuan Y, Kummer S, L’Italien G, Revicki D. Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes. 2012;10:92. doi: 10.1186/1477-7525-10-92.
    1. Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J. Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes. 2014;12:90. doi: 10.1186/1477-7525-12-90.
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123. doi: 10.1001/archneur.1989.00520460115022.
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–343. doi: 10.3109/07853890109002087.
    1. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010;25:805–822. doi: 10.1002/mds.22989.
    1. Gencay-Can A, Can SS. Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. Rheumatol Int. 2012;32:27–31. doi: 10.1007/s00296-010-1558-3.
    1. Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res. 2000;9:499–508. doi: 10.1023/A:1008960710415.
    1. Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics. 2003;21:341–349. doi: 10.2165/00019053-200321050-00005.
    1. Blackburn S, Humphrey L, McCool R, Panter C, Young V, Peterson S, Mitchell L, Machouf N, Scott J: Interviews with patients with chronic hepatitis C virus infection document unmet needs, content validity, and comprehension of PROs for Clinical Trials. Poster presented at the 18th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 18-22, 2013, New Orleans, LA, USA
    1. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35:704–708. doi: 10.1053/jhep.2002.31311.
    1. Versteegh MM, Rowen D, Brazier JE, Stolk EA. Mapping onto EQ-5D for patients in poor health. Health Qual Life Outcomes. 2010;8:141. doi: 10.1186/1477-7525-8-141.
    1. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Berlin: Springer; 2007.
    1. Scott J, Gilles L, Fu M, Peeters M, Brohan E, Amatya R, Jessner W, Beumont-Mauviel M: Adding simeprevir to pegylated interferon-α/ribavirin for HCV shortens time with patient-reported symptoms and impairment in quality of life: results from the simeprevir Phase III QUEST-1, QUEST-2 and PROMISE studies. Poster presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Nov 1-5, 2013, Washington, DC, USA
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren